Restore Thyroid Health with a Physiology Approach

Restore Thyroid Health With a Physiology-First Approach

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I walk you through a practical, physiology-first approach to thyroid care that explains why relying on thyroid-stimulating hormone (TSH) alone often misguides treatment and how a focus on tissue-level thyroid biology transforms outcomes. I unpack how the body converts thyroxine (T4) into triiodothyronine (T3), why deiodinase enzymes (D1, D2, D3) and reverse T3 (rT3) determine real-world metabolic status, and how stress, inflammation, insulin resistance, aging, toxins, and nutrient deficits alter conversion. I present a step-by-step testing and treatment framework that includes free T3 (FT3), free T4 (FT4), rT3, ferritin, and thyroid antibodies, along with targeted nutrition, sleep, stress modulation, mitochondrial support, and precision thyroid pharmacology (levothyroxine, liothyronine, and desiccated thyroid). I describe how integrative chiropractic care improves autonomic balance, breathing mechanics, and movement health to support endocrine outcomes. My goal is to help you align lab insights with tissue physiology so patients feel better in the places that matter most: heart, brain, muscle, gut, skin, and bone.

Why TSH Alone Misses Tissue Hypothyroidism

When patients arrive with fatigue, cold intolerance, constipation, hair thinning, slowed cognition, depressive symptoms, or reduced exercise tolerance—and yet their TSH is “normal”—I return to one foundational truth: patients live at the receptor, not in the pituitary. The pituitary sits in a privileged conversion environment, rich in DIO2, which allows it to maintain normal local T3 signaling even when peripheral tissues have low T3. As a result, TSH can appear reassuring even while the body’s tissues remain hypothyroid (Biondi & Wartofsky, 2014; Hoermann et al., 2015).

Key points:

• TSH is a screening tool, not a definitive treatment monitor. It reflects pituitary exposure rather than tissue bioavailability of thyroid hormone (Biondi & Wartofsky, 2014).
• Pituitary-thyroid biology is unique. Robust D2 activity in the pituitary can sustain local T3 while skeletal muscle, myocardium, and liver remain under-supplied (Hoermann et al., 2015).
• Clinical implication: Normal TSH with persistent symptoms is physiologically consistent with tissue hypothyroidism.

What I measure and why:

• Free T3 (FT3): The active hormone at nuclear receptors, driving gene transcription for metabolism and energy.
• Free T4 (FT4): The substrate for conversion.
• Reverse T3 (rT3): A competitive, inactive stereoisomer that crowds receptors, signaling stress physiology and conversion shunting.
• Ferritin and micronutrients: Iron and selenium are critical to deiodinase function and thyroid enzyme systems.

In practice, this comprehensive view consistently clarifies why patients “don’t feel well” despite “normal labs” (Biondi & Wartofsky, 2014; Maia et al., 2011; Peeters et al., 2003).

Thyroid Physiology 101: Why T3 Is The Metabolic Driver

Thyroid physiology is both elegant and exacting. The thyroid gland secretes T4, a prohormone, and smaller amounts of T3, the bioactive hormone that binds thyroid hormone receptors to regulate mitochondrial biogenesis, thermogenesis, lipid turnover, cardiac inotropy and chronotropy, and neurocognitive speed.

• T4-to-T3 conversion: The majority of circulating T3 is produced outside the gland by deiodinases—primarily D1 (liver, kidney) and D2 (skeletal muscle, brain, pituitary) (Maia et al., 2011; Bianco & Gereben, 2020).
• Reverse T3 (rT3): Under stress, illness, or inflammation, D3 activity rises, shunting T4 to rT3 and inactivating T3 into T2 (Peeters et al., 2003). Elevated rT3 acts as a functional brake, occupying receptor sites without activation—an effective block on T3 signaling.
• Receptor reality: Patients live at the receptor. FT3 must be available to tissues, and rT3 must be minimized to prevent competitive blockade. That is why FT3 and rT3 together tell a more complete story than TSH alone.

Clinical translation:

• High-normal FT4 + low FT3 + high rT3 is a signature of conversion dysfunction. Patients feel hypothyroid even when TSH looks “fine.”
• Correcting this pattern restores energy, warmth, cognition, bowel motility, and exercise tolerance in real life (Biondi & Wartofsky, 2014; Hoermann et al., 2015; Wang et al., 2019).

Deiodinases D1, D2, D3: The Gatekeepers Of Tissue Thyroid Status

Deiodinases determine whether T4 is converted to T3 (active) or rT3 (inactive). Understanding how these enzymes respond to physiology is the key to personalized therapy:

• D1 and D2 (activation): Convert T4 to T3. Suppressed by chronic stress, glucocorticoids, inflammation, illness, and nutrient deficits (Maia et al., 2011; Bianco & Gereben, 2020).
• D3 (inactivation): Converts T4 to rT3 and T3 to T2; upregulated in stress, illness, and certain tissue contexts (Peeters et al., 2003; Wajner & Maia, 2012).

What depresses conversion:

• Stress and cortisol: Downregulate D1/D2 and upregulate D3 (Fliers et al., 2015).
• Inflammation (IL-6, TNF-α): Disrupts deiodinase function and hormone transport (Boelen et al., 2011).
• Insulin resistance: Alters hepatic deiodinase activity and binding proteins (Liu et al., 2017).
• Nutrient deficits: Low selenium, iron, and zinc blunt conversion and receptor function (Rayman, 2012; Zimmermann, 2006).
• Aging: Natural drift toward lower D1/D2 activity and higher D3 activity (Peeters et al., 2005).

Why this matters: If D2 is suppressed and D3 is elevated, the pituitary may still show normal TSH, but the tissues lack T3. Integrating this enzyme biology into clinical protocols is what unlocks better outcomes.

Low T3 Syndrome, Reverse T3 Dominance, and Cardiac Risk

Cardiology provides a sobering lens on thyroid physiology: in conditions like myocardial infarction and heart failure, low FT3 consistently correlates with higher mortality and worse outcomes, independent of TSH (Iervasi et al., 2003; Pingitore et al., 2019).

Physiologic mechanisms:

• T3 and the heart: Regulates calcium handling proteins (e.g., SERCA2a), myosin heavy chain isoforms, and beta-adrenergic signaling. Low T3 reduces contractility, stroke volume, and cardiac output; raises QTc risk; and impairs endothelial function (Pol et al., 2010).
• D3 upregulation in illness: Increases rT3 within the myocardium, further restricting local T3 action (Wajner & Maia, 2012).

Clinical implication: Treat the conversion pattern and tissue T3 availability, not just the TSH. In my practice, improving FT3 and lowering rT3—alongside ferritin repletion, inflammation control, and careful dosing—often parallels better exercise tolerance, steadier rhythm metrics, and improved quality of life.

The Limits Of T4-Only Therapy And When To Consider T3 Or Combination Therapy

Levothyroxine (T4) reliably lowers TSH, but symptom relief may lag if conversion is impaired or rT3 is high. This is especially common in stressed, inflamed, insulin-resistant, or nutrient-deficient patients.

• Assumption of uniform conversion: T4-only therapy presumes robust, consistent T4-to-T3 conversion across tissues—an assumption that fails in many real-world contexts.
• Physiologic cap: Because the thyroid normally contributes a meaningful fraction of T3 directly, shutting down endogenous output and relying on peripheral conversion can leave patients T3-insufficient at the tissue level.
• Clinical pattern: Normal TSH, high-normal FT4, low-normal FT3, elevated rT3, persistent symptoms.

Evidence-informed options:

• Optimize T4 only if FT4 is low and rT3 is not elevated.
• Add liothyronine (T3) in carefully titrated doses to raise tissue T3 when conversion is impaired (Fadeyev et al., 2010; Biondi & Wartofsky, 2014).
• Use combination therapy (T4+T3) in select patients—particularly with conversion inefficiencies or DIO polymorphisms (Jonklaas et al., 2014; Panicker et al., 2009).

My rationale is simple: provide the bioactive hormone in a physiologic pattern, reduce rT3 pressure, and support the enzymes and tissues that convert and use thyroid hormone.

Comprehensive Thyroid Testing: Measure What Matters

I standardize evaluation so we can act with clarity:

• Core thyroid markers:
  • TSH for screening and trend context
  • Free T4 (FT4)
  • Free T3 (FT3)
  • Reverse T3 (rT3)
  • Thyroid antibodies (TPOAb, TgAb) to evaluate autoimmunity
• Physiologic context:
  • Ferritin, iron/TIBC, selenium, zinc, vitamin D
  • Fasting insulin, HOMA-IR, lipids, hs-CRP, A1c, liver enzymes
  • Vitals (heart rate, blood pressure), body temperature trends
  • AM cortisol and diurnal patterns when stress is a driver

Interpretation keys:

• High-normal FT4 + low FT3 + elevated rT3: Conversion shunting and D3 upregulation.
• Normal/suppressed TSH with above pattern: Pituitary D2 efficiency, not global euthyroidism.
• Low ferritin (<50–70 ng/mL in symptomatic women): Common conversion bottleneck.
• High hs-CRP/insulin resistance: Inflammatory and metabolic barriers to T3 generation and action.

This lab constellation guides targeted action instead of trial-and-error dosing (Jonklaas et al., 2014; Zimmermann, 2006).

Treatment Blueprint: Physiologic, Layered Strategies That Work

My stepwise plan targets the exact bottlenecks holding patients back. Each element is chosen because it directly influences deiodinase activity, hormone transport, receptor signaling, or cellular energy.

1. Stress and Autonomic Modulation

• Techniques: Diaphragmatic and box breathing, HRV biofeedback, gentle cervical/thoracic mobilization, and vagal-toning practices.
• Why it works: Lowering cortisol and catecholamines restores D1/D2 activity and reduces D3-driven rT3, helping T4 convert to T3 (Thayer & Lane, 2009; Fliers et al., 2015).
• Chiropractic integration: Autonomic rebalancing is a core competency within my integrative chiropractic approach.

2. Anti-Inflammatory Nutrition And Metabolic Reset

• Focus: Mediterranean-pattern diet, glycemic control, omega-3s, polyphenols (e.g., curcumin, resveratrol), adequate protein, fewer ultra-processed foods.
• Why it works: Reduces IL-6/TNF-α signaling, improves insulin sensitivity, supports hepatic conversion and thyroid transport (Esposito et al., 2004; Liu et al., 2017).

3. Micronutrient Repletion For Enzyme Systems

• Nutrients: Selenium (100–200 mcg/day), iron (replete ferritin to ~70–100 ng/mL when indicated), zinc (8–15 mg/day), vitamin D (optimize 40–60 ng/mL).
• Why it works: Selenium is integral to deiodinases, iron supports thyroid peroxidase and oxygen delivery, and zinc assists receptor function (Rayman, 2012; Zimmermann, 2006).

4. Mitochondrial Support

• Agents: CoQ10, acetyl-L-carnitine, alpha-lipoic acid, magnesium, B-complex.
• Why it works: T3 drives mitochondrial biogenesis; supporting mitochondria improves ATP output and fatigue recovery (Wallace, 2013).

5. Sleep Architecture And Circadian Repair

• Interventions: Sleep consistency, darkness hygiene, morning light exposure, nasal breathing, OSA screening when needed.
• Why it works: Quality sleep stabilizes the HPA axis, reducing rT3 pressure and improving conversion (Leproult et al., 2014).

6. Precision Thyroid Therapy

• Options: T4 optimization when appropriate; low-dose liothyronine (T3) add-on or T4+T3 combination therapy in conversion-impaired cases; cautious use of desiccated thyroid with standardized lab timing and split dosing (Jonklaas et al., 2014; Fadeyev et al., 2010).
• Dosing principles: Start low, go slow; split T3 dosing to avoid peaks; monitor HR, BP, and in select cases QTc.

7. Exercise Programming

• Plan: Low-to-moderate aerobic plus progressive resistance 2–4 days/week; avoid early overtraining.
• Why it works: Improves insulin sensitivity, mitochondrial efficiency, autonomic balance, and bone density—synergistic with T3’s roles (Holloszy, 2008).

8. Environmental Detoxification

• Steps: Reduce plastics/BPA, improve air/water filtration, and nutritionally support phase I/II detox capacity.
• Why it works: Endocrine disruptors impair deiodinase expression and receptor function (Zoeller et al., 2012).

We reassess labs at 8–12 weeks and iterate based on physiology and the patient’s lived experience.

Pharmacology In Practice: Levothyroxine, Liothyronine, And Desiccated Thyroid

Optimizing therapy requires respecting pharmacokinetics and standardizing lab timing so decisions align with physiology.

• Levothyroxine (T4): Half-life ~7 days; TSH reflects weeks of exposure. Dose changes require time to equilibrate (Jonklaas et al., 2014).
• Liothyronine (T3): Shorter half-life (~18–24 hours), with peaks 2–4 hours post-dose and afternoon troughs. I favor small, split doses to keep exposure smooth (Wiersinga, 2014).
• Desiccated thyroid: Contains both T4 and T3. Split dosing reduces T3 peaks and afternoon crashes; standardized lab timing avoids misinterpretation (Hoang et al., 2013).

Standardizing laboratory timing:

• I draw free T3 at 5–6 hours post morning dose. This mid-curve snapshot avoids post-dose spikes and late troughs, making serial values comparable and actionable.

Bridging from T4 to desiccated thyroid:

• For a patient on 75 mcg levothyroxine, I often overlap half-dose T4 with half-dose desiccated thyroid for 2 weeks to respect T4’s 7-day half-life, then discontinue T4 and continue the full desiccated dose—rechecking labs once steady state is achieved.

Afternoon T3 support:

• For primary hypothyroid patients who “hit the wall” after lunch, adding a small afternoon dose of T3 (desiccated thyroid or liothyronine) smooths the curve and stabilizes energy for school, work, and training demands.

Safety cues and adjustments:

• T3 excess looks like headache, tremor, anxiety, resting tachycardia, and insomnia. I reduce the dose by a small step and consider more granular split dosing to maintain benefits without overshoot.

Hashimoto’s Thyroiditis, Iodine Physiology, And Autoimmunity

Goals with Hashimoto’s:

• Preserve native thyroid function, personalize replacement therapy, and reduce autoimmune drivers through gut and immune modulation.
• I measure TPOAb and TgAb initially and may recheck to track the trajectory. Selenium repletion and gut repair strategies can lower oxidative stress and potentially reduce antibody titers (Ventura et al., 2017).

Iodine: handle with nuance

• Cells use sodium-iodide symporters (NIS) to uptake iodine. When repletion begins, TSH can transiently rise to upregulate NIS; this is not always a sign of worsening hypothyroidism if FT3/FT4 and clinical status are improving (Zimmermann & Boelaert, 2015).
• I prefer diet-first iodine (seafood, sea vegetables), cautious supplementation when indicated, and pairing with selenium and zinc.
• Important caution: Excess iodine can exacerbate autoimmunity in susceptible patients; dosing must be individualized (Leung & Pearce, 2019).

Integrative Chiropractic Care: Autonomic Balance, Breathing Mechanics, And Movement Health

As a chiropractor and advanced practice nurse, I see the endocrine and musculoskeletal systems as inseparable. My integrative chiropractic care supports thyroid outcomes by modulating the autonomic nervous system, improving breathing mechanics, and optimizing movement efficiency.

• Autonomic regulation: Gentle cervical and thoracic mobilization, breathing drills, and vagal-toning techniques reduce sympathetic overdrive. Lowering cortisol and catecholamines favors D1/D2 activity, reduces D3 pressure, and enhances T4-to-T3 conversion (Thayer & Lane, 2009).
• Breath mechanics and rib cage mobility: Better diaphragm function improves oxygen delivery and venous return, aiding mitochondrial performance and exercise tolerance—where T3 is critical.
• Posture and gait efficiency: Reducing mechanical nociception and improving movement patterns lowers neuroinflammatory load and physiologic stress, supporting hormone utilization.
• Exercise prescription: Progressive resistance and aerobic conditioning build mitochondrial capacity, insulin sensitivity, and bone integrity—synergistic with thyroid optimization (Holloszy, 2008).

Clinical observations from my work and platforms (pushasrx.com and LinkedIn):

• Patients with chronic neck/upper thoracic tension and poor breathing mechanics often present with higher rT3 and lower FT3. After targeted mobilization, myofascial work, breath training, and sleep optimization—paired with nutrition—FT3 rises, and rT3 falls over 8–12 weeks. These changes coincide with warmer hands, steadier energy, improved bowel motility, and better HRV metrics.

Explore my clinical perspectives and ongoing updates:

• pushasrx.com
• linkedin.com/in/dralexjimenez

Psychiatric And Pain Connections: Mood, Sleep, And Thyroid Biology

Thyroid biology interlaces with neurotransmission and sleep architecture. Low FT3 increases the odds of depressive symptoms and sleep disruption, and T3 augmentation has shown benefit in treatment-resistant depression for select patients under psychiatric supervision (Kelly & Lieberman, 2009; Cooper-Kazaz et al., 2007). In pain contexts, long-term opioid therapy can shift endocrine axes, including lowering FT3 and raising rT3. Optimizing FT3—with careful safety monitoring—often supports better mood, sleep continuity, and pain tolerance, improving adherence to nonpharmacologic pain strategies.

Bone Health, Safety, And Myths

There is a common fear that optimizing FT3 levels will inevitably lead to osteoporosis. Evidence indicates that when patients remain euthyroid and T3 exposure is kept within physiologic bounds, bone mineral density is not significantly compromised (Flynn et al., 2010). The danger comes from overtreatment, not careful, physiology-aligned care.

My safety framework:

• Resist overshooting FT3.
• Monitor heart rate, blood pressure, and in select contexts, QTc.
• Support bone with resistance training, adequate protein, vitamin D, calcium, magnesium, and sleep.

Putting It All Together: A Stepwise Clinical Workflow

• Symptoms and history:
  • Energy, temperature regulation, cognition, mood, sleep, bowels, hair/skin, palpitations, exercise tolerance, menstrual patterns.
• Labs:
  • FT3, FT4, rT3, TSH (context), TPOAb/TgAb, ferritin, iron/TIBC, selenium, zinc, vitamin D, metabolic and inflammatory markers, liver enzymes.
• Physiology-first interpretation:
  • Identify conversion dysfunction (high-normal FT4 + low FT3 + high rT3).
  • Recognize pituitary-peripheral disconnect.
  • Find drivers: stress, inflammation, insulin resistance, nutrient deficits, toxins, aging.
• Intervention:
  • Stress/autonomic modulation and integrative chiropractic care.
  • Anti-inflammatory nutrition and metabolic reset.
  • Micronutrient repletion (selenium, iron, zinc, vitamin D).
  • Mitochondrial supports and graded exercise.
  • Precision thyroid therapy (T4, T3, or combination) with standardized lab timing and split dosing.
• Monitoring:
  • Recheck labs in 8–12 weeks.
  • Track HR, BP, body temperature, HRV, sleep quality, bowel frequency, hair shedding, exercise tolerance, and mood.
  • Adjust iteratively, guided by physiology and lived experience.

Clinical Vignettes: From “Normal TSH, Miserable Patient” To Measurable Recovery

• Pattern: Patient with normal TSH, high-normal FT4, low FT3, elevated rT3, low ferritin, and persistent fatigue, cold intolerance, constipation, and hair thinning.
• Plan: Lower physiologic stress via autonomic modulation; replete ferritin and selenium; adopt anti-inflammatory nutrition; add low-dose liothyronine split dosing; standardize labs at 5–6 hours post-dose.
• Outcome: Over weeks to months, FT3 rises, rT3 falls, hands warm up, bowel regularity returns, hair shedding declines, and cognitive speed improves. This is what physiology-aligned care looks like in real life.

Key Takeaways For Patients And Clinicians

• TSH is a screening tool; FT3, FT4, and rT3 define tissue thyroid status.
• D1/D2/D3 orchestrate activation versus inactivation; stress and inflammation often suppress D2 and elevate D3.
• High rT3 is a physiologic brake and a sign of conversion shunting; measure it when symptoms persist.
• T4-only therapy can normalize TSH without restoring tissue T3; consider T3 add-on or combination therapy in select patients.
• Integrate chiropractic autonomic modulation, sleep and stress optimization, nutrition, and targeted exercise to amplify endocrine outcomes.
• Standardize lab timing and split dosing to match pharmacokinetics and avoid misinterpretation.

References

• American Thyroid Association guidelines on hypothyroidism. (2014). American Thyroid Association.
• Beyond the fixed dose: Combination therapy in hypothyroidism. (2015). Fliers, E., Boelen, A., & Wiersinga, W. M. The Lancet Diabetes & Endocrinology.
• Cytokines and thyroid hormone metabolism. (2011). Boelen, A., Kwakkel, J., & Fliers, E. Nature Reviews Endocrinology.
• Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism. (2013). Hoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. Thyroid.
• Guidelines for the treatment of hypothyroidism: prepared by the ATA task force on thyroid hormone replacement. (2014). Jonklaas, J., Bianco, A. C., Bauer, A. J., et al. Thyroid.
• Hypothyroidism. (2017). Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. The Lancet.
• Is pituitary TSH the sufficient measure of thyroid hormone-controlled homoeostasis?. (2015). Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. Frontiers in Endocrinology.
• Low T3 syndrome: a strong predictor of death in patients with cardiac disease. (2003). Iervasi, G., Pingitore, A., et al. The Journal of Clinical Endocrinology & Metabolism.
• Management of hypothyroid patients with combined therapy with levothyroxine and liothyronine. (2010). Fadeyev, V. V., Morgunova, T. B., Melnichenko, G. A., et al. The Journal of Clinical Endocrinology & Metabolism.
• Mediterranean diet and markers of vascular inflammation. (2004). Esposito, K., Marfella, R., et al. The American Journal of Clinical Nutrition.
• Non-thyroidal illness syndrome. (2015). Fliers, E., Bianco, A. C., Langouche, L., & Boelen, A. The New England Journal of Medicine.
• Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. (2014). Wiersinga, W. M. European Journal of Endocrinology.
• Selenium and thyroid diseases: from pathophysiology to treatment. (2012). Rayman, M. P. The American Journal of Clinical Nutrition.
• The clinical significance of subclinical thyroid dysfunction. (2008). Biondi, B., & Cooper, D. S. The Journal of Clinical Endocrinology & Metabolism.
• The human coronary collateral circulation. (2013). Seiler, C. Heart.
• The influence of iron status on thyroid function in humans. (2006). Zimmermann, M. B. Thyroid.
• The thyroid hormone economy and its disorders. (2018). Bianco, A. C., & da Conceição, R. R. Physiological Reviews.
• Thyroid hormone and cardiac function. (2019). Pingitore, A., Mastorci, F., et al. Frontiers in Endocrinology.
• Thyroid hormone and the cardiovascular system. (2010). Pol, C. J., Muller, A., & Simonides, W. S. Frontiers in Physiology.
• Thyroid hormone metabolism in critically ill patients. (2003). Peeters, R. P., Wouters, P. J., Kaptein, E., et al. The Journal of Clinical Endocrinology & Metabolism.
• Triiodothyronine augmentation in major depressive disorder. (2009). Kelly, T., & Lieberman, D. Z. Journal of Affective Disorders.
• T3 augmentation in treatment-resistant depression. (2007). Cooper-Kazaz, R., van der Deure, W. M., et al. International Journal of Neuropsychopharmacology.
• Vagal tone, autonomic regulation, and physiological resilience. (2009). Thayer, J. F., & Lane, R. D. Biological Psychology.
• Ventura: Selenium in the prevention of autoimmune thyroiditis. (2017). Ventura, M., Melo, M., & Carrilho, F. Journal of Pediatric Endocrinology & Metabolism.
• Wajner: Deiodinase type 3 in non-thyroidal illness syndrome. (2012). Wajner, S. M., & Maia, A. L. Journal of Thyroid Research.
• Wallace: Mitochondria and metabolic disease. (2013). Wallace, D. C. Annual Review of Pathology.
• Wang: Reverse T3 physiology and clinical relevance. (2019). Wang, X., et al. Endocrine.
• Zoeller: Endocrine disruptors and thyroid function. (2012). Zoeller, R. T., et al. Endocrine Reviews.
• Flynn: Serum TSH concentration and morbidity from cardiovascular disease and fractures. (2010). Flynn, R. W. V., et al. The Journal of Clinical Endocrinology & Metabolism.
• Leproult: Sleep curtailment and endocrine function. (2014). Leproult, R., et al. Proceedings of the National Academy of Sciences.
• Liu: Insulin resistance and thyroid hormone metabolism. (2017). Liu, D., et al. Metabolism.
• Leung: The complexity of iodine nutrition. (2019). Leung, A. M., & Pearce, E. N. Nature Reviews Endocrinology.
• Zimmermann & Boelaert: Iodine deficiency and thyroid disorders. (2015). Nutrition Reviews.
• Jonklaas: Evidence-based use of combination thyroid therapy. (2014). The Journal of Clinical Endocrinology & Metabolism.
• Panicker: DIO2 polymorphisms and satisfaction with LT4 therapy. (2009). The New England Journal of Medicine.